The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Objectives
The aim of the study was to evaluate darunavir and cobicistat pharmacokinetics in pregnant women with HIV‐1 infection.
Methods
This phase 3b, open‐label study enrolled HIV‐1‐infected pregnant women (18–26 weeks of gestation) receiving combination antiretroviral therapy with once‐daily darunavir/cobicistat 800/150 mg. The plasma pharmacokinetics of darunavir (total and unbound) and cobicistat...
ObjectivesAntiretroviral therapy during pregnancy is recommended to reduce the risk of mother‐to‐child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice‐daily (bid) darunavir in HIV‐1‐infected pregnant women.
MethodsHIV‐1‐infected...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.